UBS Group’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

UBS Group’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,000	Closed	-$8K	–	8345
2015 Q4	$8K	Hold	1,000	–	–	﹤0.01%	7449
2015 Q3	$8K	Hold	1,000	–	–	﹤0.01%	7435
2015 Q2	$11K	Hold	1,000	–	–	﹤0.01%	7408
2015 Q1	$14K	Hold	1,000	–	–	﹤0.01%	7369
2014 Q4	$17K	Buy	+1,000	New	+$14.6K	﹤0.01%	7903

Other funds holding INFI

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

UBS Group's INFI Position: Q3 2023 in Review

UBS Group sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2023, closing a stake of 600 shares — an estimated $126 sold.

UBS Group first reported a position in INFI in Q4 2014 and held it in 29 quarters. The position peaked at $1.03M in Q4 2015. 3 funds tracked by Wall St. Rank hold INFI as of Q3 2023.

UBS Group reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
UBS Group sold 600 Infinity Pharmaceuticals, Inc. shares in Q3 2023, an estimated $126.
UBS Group first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2014 and held it in 29 quarters.
UBS Group's Infinity Pharmaceuticals, Inc. position peaked at $1.03M in Q4 2015.
3 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.